DOXORUBICIN IN ADVANCED BREAST-CANCER - INFLUENCE OF SCHEDULE ON RESPONSE, SURVIVAL AND QUALITY-OF-LIFE

被引：65

作者：

RICHARDS, MA ^{[1
]}

HOPWOOD, P ^{[1
]}

RAMIREZ, AJ ^{[1
]}

TWELVES, CJ ^{[1
]}

FERGUSON, J ^{[1
]}

GREGORY, WM ^{[1
]}

SWINDELL, R ^{[1
]}

SCRIVENER, W ^{[1
]}

MILLER, J ^{[1
]}

HOWELL, A ^{[1
]}

RUBENS, RD ^{[1
]}

机构：

[1] CHRISTIE HOSP & HOLT RADIUM INST,DEPT MED ONCOL,CANC RES CAMPAIGN,MANCHESTER,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER | 1992年 / 28A卷 / 6-7期

关键词：

D O I：

10.1016/0959-8049(92)90447-A

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.

引用

页码：1023 / 1028

页数：6

共 30 条

[1] BAUM M, 1980, BREAST CANCER EXPT C, P223
[2] DOXORUBICIN - EFFECT OF DIFFERENT SCHEDULES ON TOXICITY AND ANTI-TUMOR EFFICACY
BIELACK, SS
ERTTMANN, R
WINKLER, K
LANDBECK, G
[J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (05): : 873 - 882
[3] THE USE OF GRANULOCYTE COLONY-STIMULATING FACTOR TO INCREASE THE INTENSITY OF TREATMENT WITH DOXORUBICIN IN PATIENTS WITH ADVANCED BREAST AND OVARIAN-CANCER
BRONCHUD, MH
HOWELL, A
CROWTHER, D
HOPWOOD, P
SOUZA, L
DEXTER, TM
[J]. BRITISH JOURNAL OF CANCER, 1989, 60 (01) : 121 - 125
[4] BRUNNER KW, 1977, CANCER, V36, P1208
[5] A COMPARISON OF 2 DOSES OF ADRIAMYCIN IN THE PRIMARY CHEMOTHERAPY OF DISSEMINATED BREAST-CARCINOMA
CARMOPEREIRA, J
COSTA, FO
HENRIQUES, E
GODINHO, F
CANTINHOLOPES, MG
SALESLUIS, A
RUBENS, RD
[J]. BRITISH JOURNAL OF CANCER, 1987, 56 (04) : 471 - 473
[6] CHLEBOWSKI RT, 1980, CANCER TREAT REP, V64, P47
[7] IMPROVING THE QUALITY-OF-LIFE DURING CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - A COMPARISON OF INTERMITTENT AND CONTINUOUS TREATMENT STRATEGIES
COATES, A
GEBSKI, V
BISHOP, JF
JEAL, PN
WOODS, RL
SNYDER, R
TATTERSALL, MHN
BYRNE, M
HARVEY, V
GILL, G
SIMPSON, J
DRUMMOND, R
BROWNE, J
VANCOOTEN, R
FORBES, JF
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (24) : 1490 - 1495
[8] CREECH RH, 1978, P AM ASSOC CANC RES, V19, P315
[9] MEASURING PSYCHOLOGICAL AND PHYSICAL DISTRESS IN CANCER-PATIENTS - STRUCTURE AND APPLICATION OF THE ROTTERDAM-SYMPTOM-CHECKLIST
DEHAES, JCJM
VANKNIPPENBERG, FCE
NEIJT, JP
[J]. BRITISH JOURNAL OF CANCER, 1990, 62 (06) : 1034 - 1038
[10] COMPARISON OF SHORT-TERM AND CONTINUOUS CHEMOTHERAPY (MITOZANTRONE) FOR ADVANCED BREAST-CANCER
HARRIS, AL
CANTWELL, BMJ
CARMICHAEL, J
WILSON, R
FARNDON, J
DAWES, P
GHANI, S
EVANS, RGB
[J]. LANCET, 1990, 335 (8683) : 186 - 190

← 1 2 3 →